To read the full story
Related Article
- Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
- Lonsurf-Bevacizumab Snags US Approval for Colorectal Cancer: Taiho
August 4, 2023
- Lonsurf-Bevacizumab Combo Nabs EU Panel Nod for Colorectal Cancer
June 27, 2023
- Lonsurf-Bevacizumab Combo Gets FDA’s Priority Review in Colorectal Cancer: Taiho
April 20, 2023
- Lonsurf-Bevacizumab Combo Extends Survival in PIII Colorectal Cancer Trial
September 14, 2022
BUSINESS
- Eisai Wins Lenvima Patent Suit in US, Barring Generic to 2036
May 30, 2025
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- Mitsubishi Re-Files NeuroDerm’s Parkinson’s Drug in US
May 30, 2025
- Towa, Sawai Log Two-Digit Growth in Operating Profit, but Industry Sees Divide: Tally
May 30, 2025
- Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…